- Conditions
- Acquired Bone Marrow Failure Syndromes, Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Biphenotypic/Undifferentiated/Prolymphocytic Leukemias, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Diffuse Large Cell Non Hodgkins Lymphoma, Follicular Lymphoma, High Grade Non-Hodgkin's Lymphoma, Adult, High Risk Anemia, Juvenile Myelomonocytic Leukemia, Lymphoblastic Lymphoma, Lymphoma, Lymphoplasmacytic Lymphoma, MRD Positive Leukemia, Mantle-Cell Lymphoma, Marginal Zone B-Cell Lymphoma, Multiple Myeloma, Myelodysplasia, Myelofibrosis, Myeloproliferative Neoplasms, Natural Killer Cell Malignancies, Plasma Cell Leukemia, Prolymphocytic Leukemia, Refractory Anemia, Small Lymphocytic Lymphoma
- Interventions
- HSCT with Non-TBI Regimen, HSCT with TBI Regimen
- Biological
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- Up to 60 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–10
of 10
matching trials from the local directory fallback.
Local D1 index available.
- Conditions
- Acute Lymphocytic Leukemia (ALL), Acute Myeloid Leukemia (AML), Burkitt's Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Lymphoblastic Lymphoma, Lymphoplasmacytic Lymphoma, Mantle-Cell Lymphoma, Marginal Zone B-Cell Lymphoma, Multiple Myeloma, Myelodysplasia, Myelofibrosis, Non-Hodgkin Lymphoma, Plasma Cell Leukemia, Prolymphocytic Leukemia, Small Lymphocytic Lymphoma
- Interventions
- Cyclophosphamide, Cyclosporine A, Fludarabine, Mycophenylate mofetil, Total Body Irradiation, Umbilical cord blood
- Drug · Radiation · Biological
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- Up to 55 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2026
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Follicular Lymphoma, Follicular Lymphoma Grade 2, Follicular Lymphoma Grade IIIa, Follicular Lymphoma, Grade 1, Lymphoma, Marginal Zone B Cell Lymphoma, Marginal Zone Lymphoma
- Interventions
- Rituximab, Umbralisib
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Acute Leukemia, Acute Lymphoblastic Leukemia/Lymphoma, Acute Myeloid Leukemia, Biphenotypic/Undifferentiated/Prolymphocytic Leukemias, Bone Marrow Failure Syndromes, Burkitt's Lymphoma, Chronic Myelogenous Leukemia, Follicular Lymphoma, Hodgkin Lymphoma, Large-cell Lymphoma, Leukemia or MDS in Aplasia, Lymphoplasmacytic Lymphoma, MRD Positive Leukemia, Mantle-cell Lymphoma, Marginal Zone B-cell Lymphoma, Multiple Myeloma, Myelodysplastic Syndrome, Myeloproliferative Neoplasms/Myelofibrosis, Natural Killer Cell Malignancies, Plasma Cell Leukemia, Prolymphocytic Leukemia, Relapsed Chronic Lymphocytic Leukemia, Relapsed Multiple Myeloma, Relapsed Small Lymphocytic Lymphoma, Relapsed T-Cell Lymphoma
- Interventions
- ATG, Cyclophosphamide, Fludarabine, MMF, Sirolimus, TBI, Umbilical cord blood cell infusion
- Biological · Drug · Radiation
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- Up to 75 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Chronic Lymphocytic Leukemia (CLL), Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), High Grade Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma (MCL), Marginal Zone B Cell Lymphoma, Small Lymphocytic Lymphoma (SLL)
- Interventions
- ME-401, Rituximab, Zanubrutinib
- Drug
- Lead sponsor
- MEI Pharma, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 97 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 23
- States / cities
- Tucson, Arizona • Corona, California • Miami, Florida + 18 more
- Conditions
- Follicular Lymphoma, Lymphoma of Mucosa-Associated Lymphoid Tissue, Lymphoma, Small Lymphocytic, MALT Lymphoma, Mantle-Cell Lymphoma, Marginal Zone B-Cell Lymphoma, Waldenstrom Macroglobulinemia
- Interventions
- Dexamethasone, Lenalidomide, Rituximab
- Drug
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2020
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Biphenotypic Leukemia, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Follicular Lymphoma, Hodgkin Lymphoma, Large-cell Lymphoma, Lymphoplasmacytic Lymphoma, Mantle-Cell Lymphoma, Marginal Zone B-Cell Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes, Natural Killer Cell Malignancies, Prolymphocytic Leukemia, Small Lymphocytic Lymphoma, Undifferentiated Leukemia
- Interventions
- Infusion of Treg
- Biological
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Any T-cell Malignancy, Burkett's Lymphoma, CD27 Expressing B-cell Malignancies for Example Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Colorectal Adenocarcinoma, Non-small Cell Lung Cancer), Hormone-refractory Prostate Adenocarcinoma, Ovarian Cancer, Mantle Cell Lymphoma, Marginal Zone B Cell Lymphoma), Primary Lymphoma of the Central Nervous System, Solid Tumors (Metastatic Melanoma, Renal (Clear) Cell Carcinoma
- Interventions
- CDX-1127
- Drug
- Lead sponsor
- Celldex Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 10
- States / cities
- Scottsdale, Arizona • Stanford, California • Rochester, Minnesota + 7 more
- Conditions
- Acute Lymphocytic Leukemia, Acute Myeloid Leukemia, Anemia, Refractory, With Excess of Blasts, Burkitt's Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia in Blast Crisis, Chronic Myeloproliferative Disease, Follicular Lymphoma, Hematologic Malignancy, High Grade Non-Hodgkin's Lymphoma, Large Cell Non-Hodgkin's Lymphoma, Lymphoblastic Lymphoma, Lymphoplasmacytic Lymphoma, Mantle-Cell Lymphoma, Marginal Zone B-cell Lymphoma, Prolymphocytic Lymphoma, Small Lymphocytic Lymphoma
- Interventions
- CD3+ Teff cells, Cyclophosphamide, Fludarabine, Total body irradiation, Treg cells, Umbilical cord blood transplantation
- Biological · Drug · Radiation
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- 18 Years to 55 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Adult Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia (CLL), Lymphoma, Follicular, Malignant Lymphoma - Lymphoplasmacytic, Mantle Cell Lymphoma Recurrent, Marginal Zone B-Cell Lymphoma, Small Lymphocytic Lymphoma, T-Cell Lymphoma, Waldenstrom Macroglobulinemia
- Interventions
- Doxycycline
- Drug
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Rochester, New York